Proactive - Interviews for investors podcast

Orthocell posts record revenue, eyes US expansion

0:00
4:53
Spola tillbaka 15 sekunder
Spola framåt 15 sekunder
Orthocell Ltd CEO and managing director Paul Anderson talked with Proactive about the company’s record quarterly revenues and strategic expansion plans. Orthocell has reported a record quarterly revenue of A$2.73 million for the June 2025 quarter, marking a 22.8% increase over the previous quarter. Anderson attributed this growth to strong demand for the company’s flagship nerve repair device, Remplir, across Australia. He explained that more than 206 surgeons are now using Remplir in over 166 hospitals, describing it as a “spectacular product launch.” The company has also taken significant steps to prepare for entry into the US market. Anderson said Orthocell has recruited 14 distributors covering over 21 states and completed its first US procedure last week. “It leaves us in such a strong position,” he said, noting that the record revenue figures do not yet include any US sales contributions. Looking ahead, Orthocell expects further growth as more hospitals and clinicians adopt Remplir in both Australia and the US. Anderson emphasized that the commercialization strategy developed domestically is now being applied internationally, which could further increase usage and revenue in the coming financial year. Visit Proactive’s YouTube channel for more interviews and updates, and don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #Orthocell #Remplir #MedicalDevices #NerveRepair #RevenueGrowth #USExpansion #Orthopaedics #HealthcareInnovation #InvestorUpdates #ProactiveInvestors

Fler avsnitt från "Proactive - Interviews for investors"